| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/06/2002 | WO2002011746A3 Chlorella preparations exhibiting immunomodulating properties |
| 09/06/2002 | WO2002010217A3 Endothelial cell expression patterns |
| 09/06/2002 | WO2001098363A3 Peptides for use in the immunotherapy of renal cell carcinoma |
| 09/06/2002 | WO2001098334A3 Streptococcus antigens |
| 09/06/2002 | WO2001085785A3 Ph domain-interacting protein |
| 09/06/2002 | WO2001079276A3 Leishmania antigens for use in the therapy and diagnosis of leishmaniasis |
| 09/06/2002 | WO2001072822B1 Genes involved in intestinal inflammatory diseases and use thereof |
| 09/06/2002 | WO2001064738A3 Heparin-binding amino acid sequences derived from human proteins facilitating penetration of a substance of interest into cells and/or cell nuclei |
| 09/06/2002 | WO2001058915A8 Human g-protein chemokine receptor (ccr5) hdgnr10 |
| 09/06/2002 | WO2001048485A9 Selecting library members capable of binding to epitopes |
| 09/06/2002 | WO2001032614A9 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 09/06/2002 | WO2001031021A9 Multiple sclerosis-related superantigen |
| 09/06/2002 | WO2001027291A9 Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice |
| 09/06/2002 | WO2001018546A9 Screening for inhibitors of 'paired helical filaments' |
| 09/06/2002 | WO2001018199A9 Chimaeric plant viruses with mucin peptides |
| 09/06/2002 | WO2001018035A9 Muc-1 derived peptides |
| 09/06/2002 | WO2001012674A9 Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof |
| 09/06/2002 | WO2000073462A9 Attenuated mutant enteropathogenic e. coli (epec) strains, process for their production and their use |
| 09/06/2002 | WO2000067761A9 Compositions and methods for identifying antigens which elicit an immune response |
| 09/06/2002 | CA2440740A1 Hla ligand database utilizing predictive algorithms and methods of making and using same |
| 09/06/2002 | CA2439492A1 Tri-hybrid melanoma antigen |
| 09/06/2002 | CA2439335A1 Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas |
| 09/06/2002 | CA2439190A1 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 09/06/2002 | CA2438960A1 Influenza vaccine formulations for intradermal delivery |
| 09/06/2002 | CA2438956A1 A vaccine composition and method of using the same |
| 09/06/2002 | CA2438696A1 Polynucleotide formulation for enhanced intracellular transfer |
| 09/06/2002 | CA2438238A1 Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders |
| 09/06/2002 | CA2437898A1 Interferon-alpha induced gene |
| 09/06/2002 | CA2434690A1 Proteins, polynucleotides encoding them and methods of using the same |
| 09/06/2002 | CA2434671A1 Methods and compositions for modulating regulation of the cytotoxic lymphocyte response by macrophage migration inhibitory factor |
| 09/06/2002 | CA2432029A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 09/06/2002 | CA2430702A1 Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus |
| 09/05/2002 | US20020124274 Delivery system |
| 09/05/2002 | US20020123614 Modified polypeptides stabilized in a desired conformation and methods for producing same |
| 09/05/2002 | US20020123517 Method for controlling cell necrosis or apoptosis |
| 09/05/2002 | US20020123481 C-fos induced growth factor (FIGF) and DNA encoding same |
| 09/05/2002 | US20020123479 Immunostimulation mediated by gene-modified dendritic cells |
| 09/05/2002 | US20020123476 For treating infectious diseases and genetic disorders through gene therapy and intracellular delivery of antisense oligonucleotides or other nucleic acid sequences |
| 09/05/2002 | US20020123472 Exposing mammal to major histocompatibility complex class I and peptide, prior to, after, or concurrently with treating mammal to kill or inactivate autoimmune cells of mammal for increasing or maintaining number of functional cells |
| 09/05/2002 | US20020123471 Useful as a gene transfer vehicle for gene therapy, i.e. of the central nervous system |
| 09/05/2002 | US20020123458 Endostatin protein and fragments thereof |
| 09/05/2002 | US20020123119 Nucleotide sequences coding enzymatic polypeptide for use in screening bactericides and for treatment and prevention of infections |
| 09/05/2002 | US20020123108 Fusion proteins between antigenic amino acid sequences and beta-2- microglobulin |
| 09/05/2002 | US20020123099 Highly expressible genes |
| 09/05/2002 | US20020123067 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 09/05/2002 | US20020123057 Screening for nucleotide sequence which code for prefrential antibodies; obtain cells, transform with expression vector coding antibody, express vector, recover antibody and nucleotide sequences expressing antibody |
| 09/05/2002 | US20020123047 dexB |
| 09/05/2002 | US20020123041 Method for treatment of canine distemper |
| 09/05/2002 | US20020123039 Peptide for use in the prevention and treatment of vial infections |
| 09/05/2002 | US20020122820 Liposome having at least one recombinant soluble MHC-peptide complex incorporated therein; may also include at least one additional signal molecule for manipulating the intensity and quality of the immune response. |
| 09/05/2002 | US20020122809 Purifying an immunogenic polysaccharide from Enterococcus faecalis by digesting the bacteria with mutanolysin/lysozyme, nucleases and pronase E; size fractionating by chromatography; selecting polysaccharide fractions |
| 09/05/2002 | US20020122808 Combination of outer-polysaccharides extracted from Brucella comprises "A" outer-polysaccharide and "M" outer-polysaccharide and "R" protein antigens. |
| 09/05/2002 | US20020122807 Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
| 09/05/2002 | US20020122804 Inhibition of transglutaminase-mediated microbial interaction with a mammalian host |
| 09/05/2002 | US20020122802 Diagnosis and treatment of malignant neoplasms |
| 09/05/2002 | US20020122795 Compositions containing gangliosides for use in the treatment of skin disorders |
| 09/05/2002 | US20020122794 Antigenic preparation for treatment or prevention of helicobacter infection |
| 09/05/2002 | US20020122791 Antigenic CK-18 compounds for therapy and diagnosis and methods for using same |
| 09/05/2002 | DE10106852A1 Entzündungshemmende Verbindungen Anti-inflammatory compounds |
| 09/04/2002 | EP1236800A2 Nucleic acids encoding interferon alpha 2, containing single nucleotide polymorphisms and methods of use thereof |
| 09/04/2002 | EP1236740A1 Vaccine against HER-2/neu oncogene-associated cancers |
| 09/04/2002 | EP1235936A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 09/04/2002 | EP1235934A2 Screening method for candidate drugs |
| 09/04/2002 | EP1235933A2 Mammalian toxicological response markers |
| 09/04/2002 | EP1235910A1 Plant virus particles with exogenous internal eitopes |
| 09/04/2002 | EP1235907A1 6 human secreted proteins |
| 09/04/2002 | EP1235862A2 A major neutralization site of hepatitis e virus and use of this neutralization site in methods of vaccination and in methods of screening for neutralization antibodies |
| 09/04/2002 | EP1235853A1 Multimeric forms of tnf superfamily ligands |
| 09/04/2002 | EP1235848A1 Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions |
| 09/04/2002 | EP1235847A2 ISOLATION OF FIVE NOVEL GENES CODING FOR NEW Fc RECEPTORS-TYPE MELANOMA INVOLVED IN THE PATHOGENESIS OF LYMPHOMA/MELANOMA |
| 09/04/2002 | EP1235843A1 26 human secreted proteins |
| 09/04/2002 | EP1235841A1 Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions |
| 09/04/2002 | EP1235837A1 Kringle domain-containing polynucleotides, polypeptides, and antibodies |
| 09/04/2002 | EP1235787A1 $g(b)2-ADRENERGIC RECEPTOR AGONISTS |
| 09/04/2002 | EP1235597A2 Nucleic acid delivery system |
| 09/04/2002 | EP1235596A2 Use of lytic toxins and toxin conjugates |
| 09/04/2002 | EP1235594A2 Inhibition of secretion from non-neuronal cells |
| 09/04/2002 | EP1235592A1 COMBINATION OF COMPOUNDS THAT INHIBIT THE BIOLOGICAL EFFECTS OF TNF-$g(a) AND CD95L IN A MEDICAMENT |
| 09/04/2002 | EP1235591A1 Vaccine adjuvants comprising ginseng plant extract and added aluminium salt |
| 09/04/2002 | EP1235590A1 A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| 09/04/2002 | EP1235589A2 Compositions comprising neisseria meningitidis antigens from serogroups b and c as well as a further antigen |
| 09/04/2002 | EP1235588A2 Systemic immune response induced by mucosal administration of lipid-tailed polypeptides without adjuvant |
| 09/04/2002 | EP1235587A2 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases comprising all-d peptides |
| 09/04/2002 | EP0941251B1 Use of an immunoglobulin preparation for producing an oral medicament preventing hemolytic uremic syndrome and preparation for the same |
| 09/04/2002 | EP0896615B1 Peptide from soluble form of acetylcholinesterase, active as a calcium channel modulator |
| 09/04/2002 | EP0789590B1 Chitosan induced immunopotentiation |
| 09/04/2002 | EP0605680B1 Infectious bovine rhinotracheitis virus mutants and vaccines |
| 09/04/2002 | CN1367836A CHP polypeptide as ligand of PAK65 |
| 09/04/2002 | CN1367834A Proteins derived from white spot syndrome virus and uses thereof |
| 09/04/2002 | CN1367833A Streptococcus pneumoniae proteins and nucleic acid molecules |
| 09/04/2002 | CN1367832A Ehrlichia canis genes and vaccines |
| 09/04/2002 | CN1367830A Cancer associated antigens and uses therefor |
| 09/04/2002 | CN1367829A Compositions and methods for therapy and diagnosis of lung cancer |
| 09/04/2002 | CN1367790A Moraxella cattarrhalis BASB114 polypeptide antigens and uses thereof |
| 09/04/2002 | CN1367688A Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to graft |
| 09/04/2002 | CN1367022A Ginseng total saponin or monomer saponin RbI vaccine immunological adjuvant application |
| 09/04/2002 | CN1367021A DNA vaccine for foot-and -mouth disease |
| 09/04/2002 | CN1367020A Nucleic acid vaccine capable of being high-effectively and safely expressed |
| 09/04/2002 | CN1090239C Recombinant virus vectors |
| 09/04/2002 | CN1090238C Process for producing enzyme |